Iron Hill Capital is a leading life sciences private equity firm that invests in products, technologies, and global businesses that advance health.

Iron Hill Capital is led by a group of  professionals with diverse backgrounds in life sciences industry, science, and finance. The team’s complementary backgrounds give Iron Hill Capital unique perspective on the key players, events, and forces shaping the life sciences industry, and allow us to identify investment opportunities.

Iron Hill Capital focuses on the life sciences markets with the strongest demand and growth potential including pharmaceuticals, biotechnology, and medical devices and conducts ongoing research aimed at a variety of opportunities in these sectors.  

In 2008, Iron Hill established an office in Shanghai, China as a resource to assist its existing and future portfolio companies in evaluating and executing cross-border strategies. Large multinationals recognized the opportunity from globalization years ago and had the management and financial resources to capture that opportunity. It is our strong belief that small and mid-sized leaders have these same opportunities, but many lack the resources to execute the strategy needed. By identifying these opportunities and providing the capital and expertise needed to execute cross-border strategies, we can invest in and accelerate the growth of those businesses.